Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.

Conclusions: The new tazarotene 0.045% lotion formulated with polymeric emulsion technology demonstrated statistically signifi-cantly superior efficacy versus vehicle and was well tolerated in pediatric and adult patients with moderate-to-severe acne in this pooled analysis of 2 vehicle-controlled phase 3 studies. J Drugs Dermatol. 2020;19(3):272-279. doi:10.36849/JDD.2020.4869. PMID: 32549090 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32549090?dopt=Abstract

Source: Journal of Drugs in Dermatology - June 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research